Market Overview

Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American


As previously disclosed, on August 14, 2018, Navidea Biopharmaceuticals,
Inc. (NYSE:NAVB) ("Navidea" or the "Company"), a company
focused on the development of precision immunodiagnostic agents and
immunotherapeutics, received a notification (the "Deficiency Letter")
from the NYSE American LLC (the "NYSE American") stating that Navidea
was not in compliance with Section 1003(a)(ii) and Section 1003(f)(v) of
the NYSE American continued listing standards, which relate to
stockholders' equity and the selling price per share of the Company's
securities. As required by the NYSE American, Navidea submitted a plan
to the NYSE American by September 14, 2018 advising of actions it has
taken or will take to regain compliance with the continued listing
standards by February 14, 2020.

On October 25, 2018, the Company received a notification (the
"Acceptance Letter") from the NYSE American that the Company's plan to
regain compliance was accepted. The Acceptance Letter also stated that
the NYSE American had inadvertently omitted an additional deficiency
from the Deficiency Letter. Specifically, the Deficiency Letter should
have stated that Navidea is not in compliance with Section 1003(a)(iii)
of the NYSE American Company Guide, which requires an issuer to have
stockholders' equity of $6.0 million or more if it has reported losses
from continuing operations and/or net losses in its five most recent
fiscal years.

The Acceptance Letter noted that Navidea had stockholders' equity of
$2.1 million as of June 30, 2018, and has reported losses from
continuing operations and/or net losses in its five most recent fiscal
years ended December 31, 2017, and its shares have been selling at a low
price per share.

The Company must provide quarterly updates to the NYSE American staff
(the "Staff") concurrent with its interim/annual SEC filings. The Staff
has granted Navidea a plan period through February 14, 2020 to regain
compliance with Sections 1003(a)(ii) and (iii), and through February 14,
2019 to regain compliance with Section 1003(f)(v), or else the Staff may
commence delisting procedures.

Navidea's Common Stock will continue to be listed on the NYSE American
while it attempts to regain compliance with the listing standards noted,
subject to Navidea's compliance with other continued listing
requirements. The Common Stock will continue to trade under the symbol
"NAVB," but will have an added designation of ".BC" to indicate that
Navidea is not in compliance with the NYSE American's listing standards.
The NYSE American notification does not affect Navidea's business
operations or its SEC reporting requirements and does not conflict with
or cause an event of default under any of Navidea's material agreements.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea's Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc 99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company's pipeline through global partnering and commercialization

For more information, please visit

Forward-Looking Statements

This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. We have based these forward-looking statements largely
on our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including, among other things: general
economic and business conditions, both nationally and in our markets;
our history of losses and uncertainty of future profitability; the final
outcome of the CRG litigation in Texas; our ability to successfully
complete research and further development of our drug candidates; the
timing, cost and uncertainty of obtaining regulatory approvals of our
drug candidates; our ability to successfully commercialize our drug
candidates; our expectations and estimates concerning future financial
performance, financing plans and the impact of competition; our ability
to raise capital sufficient to fund our development and
commercialization programs; our ability to implement our growth
strategy; anticipated trends in our business; advances in technologies;
our ability to comply with the NYSE American continued listing
standards; and other risk factors set forth in this report and detailed
in our most recent Annual Report on Form 10-K and other SEC filings. You
are urged to carefully review and consider the disclosures found in our
SEC filings, which are available at or

Investors are urged to consider statements that include the words
"will," "may," "could," "should," "plan," "continue," "designed,"
"goal," "forecast," "future," "believe," "intend," "expect,"
"anticipate," "estimate," "project," and similar expressions, as well as
the negatives of those words or other comparable words, to be uncertain
forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We undertake no
obligation to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or otherwise after
the date of this report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at